Recombinant Human HRAS cell lysate

• Cat.No.: HRAS-556HCL
• Product Overview: Human HRAS / GTPase Hras derived in Baculovirus-Insect cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls

Specification

• Source: Baculovirus-Insect Cells
• Species: Human
• Preparation method: Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
• Lysis buffer: Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Quality control Testing: 12.5% SDS-PAGE Stained with Coomassie Blue
• Recommended Usage: 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating.
• Stability: Samples are stable for up to twelve months from date of receipt at -80°C
• Storage Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Storage Instruction: Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.

Gene Information

• Gene Name: HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog [ Homo sapiens ]
• Official Symbol: HRAS
• Synonyms: HRAS; v-Ha-ras Harvey rat sarcoma viral oncogene homolog; HRAS1; GTPase HRas; p21ras; H-Ras-1; p19 H-RasIDX protein; c-has/bas p21 protein; transforming protein p21; Ha-Ras1 proto-oncoprotein; c-ras-Ki-2 activated oncogene; GTP- and GDP-binding peptide B; transformation gene: oncogene HAMSV; Ras family small GTP binding protein H-Ras; CTLO; HAMSV; K-RAS; N-RAS; RASH1; C-H-RAS; H-RASIDX; C-BAS/HAS; C-HA-RAS1
• Gene ID: 3265
• mRNA Refseq: NM_001130442
• Protein Refseq: NP_001123914
• MIM: 190020
• UniProt ID: P01112
• Chromosome Location: 11p15.5
• Pathway: ARMS-mediated activation, organism-specific biosystem; Activation of NMDA receptor upon glutamate binding and postsynaptic events, organism-specific biosystem; Activation of RAS in B Cells, organism-specific biosystem; Acute myeloid leukemia, organism-specific biosystem; Acute myeloid leukemia, conserved biosystem; Adaptive Immune System, organism-specific biosystem; Axon guidance, organism-specific biosystem
• Function: GTP binding; GTPase activity; nucleotide binding; protein C-terminus binding; protein binding

Reviews

08/15/2019

With their meticulous documentation and support, I am confident that my utilization of the HRAS protein in clinical trials will meet all necessary regulations and guidelines.

06/26/2019

Their comprehensive certificates of analysis and safety data sheets serve as testaments to their commitment to ensuring the safety and integrity of their products.

09/12/2018

Their ability to accommodate the requirements of large-scale experiments and guarantee a steady supply streamlines my research operations, eliminating any concerns related to prospective shortages.

Q&As

Are there targeted therapies specifically designed for HRAS-related cancers?

Research is ongoing, but there are emerging targeted therapies designed to address HRAS-related cancers.

Can HRAS mutations be detected through genetic testing?

Yes, genetic testing can identify HRAS mutations, aiding in the diagnosis and prognosis of certain disorders.

Can HRAS be a potential therapeutic target for non-cancerous diseases?

Yes, there is growing interest in exploring HRAS as a therapeutic target for non-cancerous diseases, such as cardiovascular disorders.

How does HRAS influence the response to certain cancer treatments?

HRAS status can impact the response to certain cancer treatments, affecting the efficacy of targeted therapies and chemotherapy.

How is HRAS involved in the regulation of the cell cycle?

HRAS regulates the cell cycle by influencing the transition between different phases, ensuring proper cell division.